Tirzepatide

Name: TIRZEPATIDE
SKU: 595
Availability: InStock

Chemical Name: Tirzepatide
Molecular Formula: C₂₂₉H₃₇₁N₆₅O₆₉
Molecular Weight: ~4850 g/mol

Product Overview

Tirzepatide is a novel investigational peptide studied for its potential effects on glucose regulation and weight management. It is a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Research indicates Tirzepatide may offer benefits in obesity, type 2 diabetes, and metabolic regulation.

Note:

For laboratory research use only.
Not intended for human consumption or therapeutic use.
Handling by trained research professionals is required.
Please see our blog for more in-depth information on Tirzepatide research developments.

Indications (Research Purposes Only)

Tirzepatide is intended for preclinical and laboratory research on:

Metabolic disorders, including obesity and type 2 diabetes
Glycemic control and insulin sensitivity
Appetite regulation and satiety mechanisms
Energy metabolism and weight reduction studies

Mechanism of Action

Tirzepatide acts through simultaneous agonism of two key metabolic receptors:

GLP-1 Receptor: Promotes glucose-dependent insulin secretion, reduces glucagon secretion, slows gastric emptying, and modulates appetite.
GIP Receptor: Enhances insulin secretion, improves postprandial glucose control, and may influence lipid metabolism.

Combined receptor activation is hypothesized to produce additive effects on weight loss and improved glycemic control.

Pharmacodynamics (Preclinical Data)

Significant body weight reduction observed in rodent and non-human primate models.
Enhanced insulin sensitivity and improved glucose tolerance in diet-induced obesity studies.
Reduction in appetite and food intake contributing to weight management.
Improved lipid profiles and hepatic lipid content reduction.

Pharmacokinetics (Preclinical Observations)

Extended half-life supporting once-weekly dosing in preclinical studies.
Dose-dependent pharmacodynamic responses observed in controlled studies.
Favorable subcutaneous bioavailability noted in animal models.

Note: Pharmacokinetic data are preclinical and may vary in human studies.

Observed Research Benefits (Summary)

Reduction in body weight
Improved insulin sensitivity and glucose control
Appetite suppression
Improved lipid metabolism

Findings are limited to non-human research models. Further studies are required to validate long-term effects.

Available Packaging Options

Single vial: 5 mg, 10 mg, or 20 mg
Three-pack (bulk option): 5 mg, 10 mg, or 20 mg

For larger quantities and bulk research orders, please contact us via our Contact Us page.

Storage and Handling

Store lyophilized (dry) vials at -20°C to -80°C prior to reconstitution.
Avoid repeated freeze-thaw cycles to maintain peptide integrity.
Do not freeze the product once it has been reconstituted with bacteriostatic or sterile water.
After reconstitution, store the vial at 2°C to 8°C (refrigerated).
Keep reconstituted solutions sealed, dry, and protected from light at all times.
Exposure to freezing temperatures after reconstitution may compromise peptide stability and reduce potency.
Retain vials in their original carton or protective case until ready for use to prevent light exposure and maintain product quality.

Disclaimer

This material is intended for laboratory research purposes only and is not intended for human or veterinary use. All research must be conducted in compliance with institutional, local, and national regulations. This material must not be used for diagnostic, therapeutic, or clinical procedures.